Description

13,33,332 equity shares of Vivo Bio Tech Ltd. (Scrip Code 511509) issued on preferential basis pursuant to warrant conversion will be listed and permitted to trade from October 13, 2025.

Summary

Vivo Bio Tech Ltd. (Scrip Code 511509) is listing 13,33,332 new equity shares of Rs. 1/- each issued at a premium of Rs. 35/- to non-promoters on a preferential basis pursuant to conversion of warrants. These shares will be listed and permitted to trade on BSE from Monday, October 13, 2025. The shares rank pari-passu with existing equity shares and are subject to lock-in restrictions.

Key Points

  • 13,33,332 equity shares of Rs. 1/- each being listed
  • Issue price: Rs. 45/- per share (Rs. 1/- face value + Rs. 35/- premium)
  • Issued to non-promoters on preferential basis
  • Shares issued pursuant to conversion of warrants
  • Distribution numbers: 19999890 to 21333221
  • ISIN: INE380K01017
  • Shares rank pari-passu with existing equity shares
  • All shares are subject to lock-in restrictions

Regulatory Changes

No regulatory changes introduced by this circular.

Compliance Requirements

Trading members of BSE are informed to note the listing of these new securities for trading purposes from the effective date.

Important Dates

  • Date of Allotment: August 12, 2025
  • Trading Commencement Date: Monday, October 13, 2025
  • Lock-in Period Expiry: April 30, 2025 (Note: This appears to be an error in the original circular as the lock-in date is before the allotment date)

Impact Assessment

This is a routine listing notification with limited market impact. The preferential allotment increases the equity capital base of Vivo Bio Tech Ltd. by 13,33,332 shares. All shares are locked-in, preventing immediate free float impact. The capital raised (approximately Rs. 60 crore at Rs. 45/- per share) provides additional resources to the company. Market participants should note the increased share capital when analyzing the company’s financials.

Impact Justification

Routine listing of preferential shares from warrant conversion with minimal market impact for a single company